Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Bioconjugation Market Report 2026: Global Size, Share, Trends and 2030 Forecast | Capitalize on Targeted Therapeutics | Thermo Fisher, Merck, Danaher, Lonza, and Agilent Lead the Industry

Thermo Fisher Scientific Inc.

Dublin, Oct. 21, 2026 -- "Bioconjugation Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global bioconjugation market is experiencing rapid growth, supported by expanding biologics research, increased development of antibody-based therapeutics, and rising demand for advanced diagnostic assays. The market is projected to grow from $6.12 billion in 2025 to $6.89 billion in 2026, representing a compound annual growth rate (CAGR) of 12.5%.

Growth during the historical period has been driven by greater use of protein-labeling techniques, increased research involving biologics, and wider availability of standardized bioconjugation kits. These factors have enabled pharmaceutical companies, biotechnology businesses, diagnostic laboratories, and research institutions to improve the consistency and efficiency of workflows involving antibodies, proteins, peptides, oligonucleotides, and other biomolecules.

The bioconjugation market is forecast to reach $11.12 billion by 2030, expanding at a CAGR of 12.7%. Key growth drivers include increasing investment in precision medicine, development of targeted drug conjugates, expansion of companion diagnostics, and growing use of conjugated biomolecules in medical imaging. Demand for scalable, reproducible, and high-purity conjugation workflows is also expected to strengthen market opportunities.

Targeted therapeutics are becoming a major catalyst for bioconjugation market growth. Bioconjugation technologies enable drugs to be linked precisely to targeting molecules, supporting selective delivery to diseased cells while improving therapeutic performance and reducing off-target effects. This capability is particularly important in the development of antibody-drug conjugates, peptide-drug conjugates, and nucleic acid-based treatments.

According to West China Hospital, Sichuan University, more than 47 new targeted therapeutics were approved by the U.S. Food and Drug Administration in 2023. These products represented approximately 85.5% of all new drug approvals during the year, highlighting the growing emphasis on precision-targeted treatment strategies in the United States.

Innovation across the bioconjugation industry is increasingly centered on site-specific techniques, advanced linker chemistries, automated platforms, and high-purity reagents. Developers are prioritizing technologies that improve coupling stability, product uniformity, scalability, and reproducibility. Enhanced stability and precise molecular attachment can help biopharmaceutical researchers optimize safety, efficacy, and manufacturing consistency.

In August 2023, BOCSCI Inc. launched its XDC bioconjugation platform to support the optimized synthesis of complex bioconjugates. The platform incorporates strategies such as unnatural amino acid incorporation, engineered cysteine conjugation, enzyme-assisted ligation, and glycoconjugation generation. It is designed to facilitate the production of antibody-drug conjugates, small interfering RNA conjugates, and other targeted drug-delivery molecules.

Merger and acquisition activity is also strengthening industry capabilities. In July 2023, Biosynth Carbosynth acquired Celares for an undisclosed amount. The transaction expanded Biosynth's bioconjugation expertise and polymer-based drug-delivery capabilities, supporting customized conjugation of antibodies, antigens, and peptides for pharmaceutical and diagnostic applications from development through commercialization.

Tariffs are creating additional challenges for the bioconjugation market by increasing the cost of imported specialty reagents, linkers, enzymes, chromatography materials, and laboratory instruments. Pharmaceutical and biotechnology organizations in North America and Europe are particularly exposed because of their dependence on imported consumables. Export-oriented suppliers in Asia-Pacific are also facing higher production costs. While these pressures can increase operating expenses and extend procurement timelines, they are encouraging regional reagent production, domestic supplier development, and investment in more resilient life sciences supply chains.

Markets Covered:
1) By Product and Service: Consumables; Instruments; Service
2) By Biomolecule Type: Antibodies; Proteins; Peptides; Oligonucleotides; Other Biomolecules
3) By Technique: Chemical Conjugation; Enzyme-Mediated Conjugation; Click Chemistry; Photoreactive Crosslinking; Other Techniques
4) By Application: Therapeutics; Research and Development; Diagnostics
5) By End Use: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CRO) and Contract Manufacturing Organizations (CMOs); Academic and Research Institutes; Hospitals, Clinical and Diagnostic Laboratories

Subsegments:
1) By Consumables: Reagents; Buffers; Linkers; Kits; Resins; Chromatography Materials; Protein Purification Materials
2) By Instruments: Chromatography Systems; Spectroscopy Systems; Electrophoresis Systems; Automated Conjugation Platforms; Imaging Systems; Bioreactors
3) By Service: Custom Conjugation Services; Antibody Modification Services; Protein Labeling Services; Contract Research Services; Analytical Testing Services; Purification Services

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Report AttributeDetails
No. of Pages250
Forecast Period2026-2030
Estimated Market Value (USD) in 2026$6.89 Billion
Forecasted Market Value (USD) by 2030$11.12 Billion
Compound Annual Growth Rate12.7%
Regions CoveredGlobal

The companies featured in this Bioconjugation market report include:

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Lonza Group AG
  • Agilent Technologies Inc.
  • Charles River Laboratories International Inc.
  • Sartorius AG
  • Bio-Rad Laboratories Inc.
  • Vector Laboratories Inc.
  • Promega Corporation
  • LGC Biosearch Technologies Ltd.
  • TriLink BioTechnologies LLC
  • Creative PEGWorks Inc.
  • Lumiprobe Corporation
  • Biotium Inc.
  • Jena Bioscience GmbH
  • Quanta BioDesign Ltd.
  • Setareh Biotech Inc.
  • Baseclick GmbH
  • Biosynth Carbosynth Ltd.
  • Glen Research Inc.
  • BroadPharm Inc.
  • Biorbyt Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/kbatrw

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. AIGlobal Bioprocessing Reagent Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, Danaher, Merck KGaA and Sartorius Accelerate AI and Single-Use SystemsCompanies: Thermo Fisher Scientific Inc.Danaher CorporationMerck KGaABoost ROI via single-use systems, AI optimization and continuous processing to cut capital costs, contamination and downtime while improving yield, scalability and efficiency.
  2. Biotech & pharmaGlobal Bioprocessing Support Services Market Report 2026 | Capitalize on $4.13B by 2030 as Thermo Fisher, Merck, Sartorius and Samsung Biologics Scale Single-Use SolutionsCompanies: Thermo Fisher Scientific Inc.Boost ROI by outsourcing services, adopting single-use integrated platforms, and standardizing scale-up, optimization and compliance to cut costs and speed production.
  3. Global Cell Culture Media and Single-Use Reagents Market Report 2026 | Capitalize on 13.6% CAGR to $8.34B by 2030 with Thermo Fisher, Merck, Sartorius and LonzaCompanies: Thermo Fisher Scientific Inc.Boost ROI with integrated single-use bioreactors that reduce contamination, setup time, cleaning, footprint and operating costs while improving scalability.
  4. Upstream Bioprocessing Equipment Market Report 2026: Forecast to 2030 | Accelerate Single-Use Scale-Up as Thermo Fisher, Merck, Danaher, Sartorius and Repligen Drive 10.9% CAGRCompanies: Thermo Fisher Scientific Inc.Danaher Corporation"Upstream Bioprocessing Equipment Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  5. Cell-Based Biological Reagents Global Market Report 2026-2030 | Capitalize on 8.6% CAGR | Thermo Fisher, Merck, Danaher and Lonza Lead the IndustryCompanies: Thermo Fisher Scientific Inc.Danaher Corporation"Cell-based Biological Reagents Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  6. FinanceGlobal Human Osteoblasts Market Report 2026 | Capitalize on $53.09 Billion Revenue Share by 2030 as Merck KGaA, Thermo Fisher Scientific, Lonza and STEMCELL Lead the IndustryCompanies: Merck KGaAThermo Fisher Scientific Inc."Human Osteoblasts Market Report 2026" has been added to ResearchAndMarkets.com's offering.